Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

This content is for healthcare professionals only.

Please confirm you are a healthcare professional.

Yes
No

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

iwCAR-T 2020

The International Workshop on CAR-T 2020 took place October 29–30th and highlighted recent updates in CAR T-cell therapy across a variety of hematological oncology indications.

Some of the world’s leading clinical researchers shared their perspectives on how to place our evolving understanding in a clinical context and thereby optimize clinical care.

The full series of presentations can be viewed on-demand below.

Day 1 Day 2 CAR-T & Cellular Therapy Focus

Day One

Day one of the meeting featured sessions on CAR-T in ALL, AML and CLL.

Session I: CAR-T in ALL
  • Novel CAR-T approaches for ALL: Rebecca Gardner
  • CAR-T in adult ALL; Claire Roddie
  • Allogeneic CAR-T in ALL: Bijal Shah
  • Remission & Persistence: Shannon Maude
Session I
Session II: CAR-T in AML
  • Overview: Saar Gill
  • CART vs BITE for AML: John DiPersio
  • NKG2D and anti-CD33 CART: David Sallman
Session II
Session 3: CAR-T in CLL
  • Update CLL CAR-T trial landscape/JCAR; Tanya Siddiqi
  • The role of CLL tumor cells in resistance to anti-CAR-T cell therapy: Joseph Melenhorst 
  • Long-term outcomes of anti-CD19 CAR-T in R/R CLL: David Porter
Session III

Day Two

Day two of the meeting featured sessions on CAR-T in lymphoma, myeloma and the evolution of cellular therapies.

Session I: CAR-T in ALL
  • Novel CAR-T approaches for ALL: Rebecca Gardner
  • CAR-T in adult ALL; Claire Roddie
  • Allogeneic CAR-T in ALL: Bijal Shah
  • Remission & Persistence: Shannon Maude
Session I
Session II: CAR-T in AML
  • Overview: Saar Gill
  • CART vs BITE for AML: John DiPersio
  • NKG2D and anti-CD33 CART: David Sallman
Session II
Session 3: CAR-T in CLL
  • Update CLL CAR-T trial landscape/JCAR; Tanya Siddiqi
  • The role of CLL tumor cells in resistance to anti-CAR-T cell therapy: Joseph Melenhorst 
  • Long-term outcomes of anti-CD19 CAR-T in R/R CLL: David Porter
Session III

Check out our latest CAR-T content!

View all
iwCAR-T 2020 Presentations 0:00
iwCAR-T 2020 Presentations

CAR-T channel

Our CAR-T Channel examines the latest updates across the field.

With content featuring expert interviews from major international congresses, this is one for your bookmarks!

To keep updated on all the latest in CAR-T, subscribe to our newsletter here.

The content of VJHemOnc is intended for healthcare professionals